Skip to content
The Nexus
DossierENTITY

Amylyx Pharmaceuticals

Coverage of Amylyx Pharmaceuticals in the Nexus archive.

Earliest in view: Jul 1 · 08:30 UTCMost recent: Jul 16 · 10:30 UTC
Co-mentioned in this coverage
avexitidetopic2rare endocrine disordertopic1ALStopic1stomach-reducing surgerytopic1Biogenorganization1post-bariatric hypoglycemiatopic1diranersentopic1Alzheimer’s diseasetopic1tautopic1
Recent coverage
  • HEALTHJul 16 · 10:30 UTCSTAT NEWS
    STAT+: Amylyx nears pivotal endocrine drug study readout

    Amylyx Pharmaceuticals will release results this quarter from a pivotal study of avexitide, a drug targeting severe, uncontrolled drops in blood sugar after stomach-reducing weight-loss surgery. The company previously voluntarily withdrew an ALS drug after a follow-on study showed it lacked efficacy.

  • HEALTHJul 1 · 08:30 UTCSTAT NEWS
    STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch

    STAT’s biotech scorecard for Q3 highlights key events for Amylyx Pharmaceuticals and Biogen. Amylyx will report Phase 3 results for avexitide in post-bariatric hypoglycemia, while Biogen will present detailed data from a mid-stage Alzheimer’s trial for diranersen on July 14.